Literature DB >> 7607720

Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation.

N Seyedi1, X Xu, A Nasjletti, T H Hintze.   

Abstract

Our goal was to determine whether angiotensin II (Ang II) and its metabolic fragments release nitric oxide and the mechanisms by which this occurs in blood vessels from the canine heart. We incubated 20 mg of microvessels or large coronary arteries in phosphate-buffered saline for 20 minutes and measured nitrite release. Nitrite release increased from 27 +/- 2 up to 103 +/- 5, 145 +/- 17, 84 +/- 4, 107 +/- 16, and 54 +/- 4 pmol/mg (P < .05) in response to 10(-5) mol/L of Ang I, II, III, IV, and Ang-(1-7), respectively. The effects of all angiotensins were blocked by N omega-nitro-L-arginine methyl ester (100 mumol/L), indicating that nitrite was a product of nitric oxide metabolism, and by Hoe 140 (10 mumol/L), a specific bradykinin B2 receptor antagonist, indicating a potential role for local kinin formation. The protease inhibitors aprotinin (10 mumol/L) and soybean trypsin inhibitor, which block local kinin formation, inhibited nitrite release by all of the angiotensins. Angiotensin nonselective (saralasin), type 1-specific (losartan), and type 2-specific (PD 123319) receptor antagonists abolished the nitrite released in response to all the fragments. Angiotensin type 1 and type 2 and receptors mediate nitrite release after Ang I, II, III, and Ang-(1-7), whereas only type 2 receptors mediate nitrite release after Ang IV. Similar results were obtained in large coronary arteries. In summary, formation of nitrite from coronary microvessels and large arteries in the normal dog heart in response to angiotensin peptides is due to the activation of local kinin production in the coronary vessel wall.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7607720     DOI: 10.1161/01.hyp.26.1.164

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  33 in total

Review 1.  Effects of antihypertensive drugs on endothelial dysfunction: clinical implications.

Authors:  Stefano Taddei; Agostino Virdis; Lorenzo Ghiadoni; Isabella Sudano; Antonio Salvetti
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism.

Authors:  R Weidenbach; R Schulz; P Gres; M Behrends; H Post; G Heusch
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

3.  Endothelial AT(2)-receptors: chicken or egg?

Authors:  Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2002-06       Impact factor: 8.739

Review 4.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

Review 5.  Novel therapeutic targets for hypertension.

Authors:  Ludovit Paulis; Thomas Unger
Journal:  Nat Rev Cardiol       Date:  2010-06-22       Impact factor: 32.419

6.  Role of angiotensin II receptor subtypes in porcine basilar artery: functional, radioligand binding, and cell culture studies.

Authors:  Atsushi Miyamoto; Ryoko Wada; Aya Inoue; Shigeru Ishiguro; James K Liao; Akira Nishio
Journal:  Life Sci       Date:  2005-10-11       Impact factor: 5.037

Review 7.  Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2008-02-07       Impact factor: 4.214

8.  Oxidative stress-mediated effects of angiotensin II in the cardiovascular system.

Authors:  Hairuo Wen; Judith K Gwathmey; Lai-Hua Xie
Journal:  World J Hypertens       Date:  2012-08-23

9.  Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation.

Authors:  Chao Fang; Evi Stavrou; Alec A Schmaier; Nadja Grobe; Mariana Morris; Andrew Chen; Marvin T Nieman; Gregory N Adams; Gretchen LaRusch; Yihua Zhou; Matthew L Bilodeau; Fakhri Mahdi; Mark Warnock; Alvin H Schmaier
Journal:  Blood       Date:  2013-02-05       Impact factor: 22.113

Review 10.  Drug Treatment of Hypertension: Focus on Vascular Health.

Authors:  Alan C Cameron; Ninian N Lang; Rhian M Touyz
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.